Tumor immune microenvironment remodeling predicts response to checkpoint inhibitor therapy.

Remodeling of tumor immune microenvironment predicts ICI response, with 40% of tumors shifting states during therapy and transitions correlating with outcomes.

• Why it matters: Understanding why some patients respond to immune checkpoint inhibitors while others do not is crucial for improving cancer treatment and personalizing therapy.
• What they did: A longitudinal single-cell RNA sequencing study analyzed 441 samples from 241 patients across ten cancers, identifying immune and stromal subtypes and deriving a 59-gene signature for response prediction.
• The result: Transitions toward inflamed or B cell-enriched states are linked to better responses and survival, enabling improved prediction models and informing rational immunotherapy strategies.